Aanastra Inc
October 15, 2024
Hunt Room
Oncology
Aanastra Inc is a start-up biopharmaceutical company focused on treating cancer with novel RNA therapeutics using its tissue-targeting peptide platform to target and rescue undruggable and mutated Tumor Suppressor Genes, edit Oncogenes and target other genetic diseases. Aanastra’s novel RNA combined with its peptides are able to efficiently target various cells, tissues and tumors in vivo (other RNA delivery strategies including AAV and LNP cannot achieve this selectivity). Aanastra’s products in preclinical development targeting P53, BRCA1 and KRAS mutations have shown remarkable antitumor effects in animal models of cancers with these mutations, as well as remarkable efficacy outside of cancer in animal models of hemophilia A and in cholesterol lowering by targeting PCSK9. Aanastra is looking to move these programs into IND-enabling studies and the team is being built around seasoned professionals with extensive experience in company building, R&D and experienced clinical advisors.
Speakers